A real-world experience of SARS-CoV-2 infection in a tertiary referral centre of Montréal: Unexpected low prevalence and low mortality.
| Title: | A real-world experience of SARS-CoV-2 infection in a tertiary referral centre of Montréal: Unexpected low prevalence and low mortality. |
|---|---|
| Authors: | Ruiz I; Liver Unit, Centre hospitalier de l'Université de Montréal (CHUM), Montréal, Québec, Canada.; Huard G; Liver Unit, Centre hospitalier de l'Université de Montréal (CHUM), Montréal, Québec, Canada.; Fournier C; Liver Unit, Centre hospitalier de l'Université de Montréal (CHUM), Montréal, Québec, Canada.; Bissonnette J; Liver Unit, Centre hospitalier de l'Université de Montréal (CHUM), Montréal, Québec, Canada.; Castel H; Liver Unit, Centre hospitalier de l'Université de Montréal (CHUM), Montréal, Québec, Canada.; Giard JM; Liver Unit, Centre hospitalier de l'Université de Montréal (CHUM), Montréal, Québec, Canada.; Villeneuve JP; Liver Unit, Centre hospitalier de l'Université de Montréal (CHUM), Montréal, Québec, Canada.; Fenyves D; Liver Unit, Centre hospitalier de l'Université de Montréal (CHUM), Montréal, Québec, Canada.; Marleau D; Liver Unit, Centre hospitalier de l'Université de Montréal (CHUM), Montréal, Québec, Canada.; Willems B; Liver Unit, Centre hospitalier de l'Université de Montréal (CHUM), Montréal, Québec, Canada.; Corsilli D; Intensive Care Unit, Centre hospitalier de l'Université de Montréal (CHUM), Montréal, Québec, Canada.; Correal F; Pharmacy Department, Centre hospitalier de l'Université de Montréal (CHUM), Montréal, Québec, Canada.; Ferreira V; Pharmacy Department, Centre hospitalier de l'Université de Montréal (CHUM), Montréal, Québec, Canada.; Martel D; Pharmacy Department, Centre hospitalier de l'Université de Montréal (CHUM), Montréal, Québec, Canada.; Mathieu A; Pharmacy Department, Centre hospitalier de l'Université de Montréal (CHUM), Montréal, Québec, Canada.; Vincent C; Liver Unit, Centre hospitalier de l'Université de Montréal (CHUM), Montréal, Québec, Canada.; Bilodeau M; Liver Unit, Centre hospitalier de l'Université de Montréal (CHUM), Montréal, Québec, Canada. |
| Source: | Canadian liver journal [Can Liver J] 2021 Nov 11; Vol. 4 (4), pp. 391-400. Date of Electronic Publication: 2021 Nov 11 (Print Publication: 2021). |
| Publication Type: | Journal Article |
| Language: | English |
| Journal Info: | Publisher: University of Toronto Press Country of Publication: Canada NLM ID: 101778326 Publication Model: eCollection Cited Medium: Internet ISSN: 2561-4444 (Electronic) Linking ISSN: 25614444 NLM ISO Abbreviation: Can Liver J Subsets: PubMed not MEDLINE |
| Imprint Name(s): | Original Publication: Toronto, ON Canada : University of Toronto Press, [2018]- |
| Abstract: | Background: The impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in patients with chronic liver disease (CLD) and liver transplant (LT) recipients remains a concern. The aim of this study was to report the impact of coronavirus disease 2019 (COVID-19) infection among patients at the tertiary health care centre Centre hospitalier de l'Université de Montréal (CHUM) during the first wave of the SARS-CoV-2 pandemic.; Methods: This real-world, retrospective cohort included all patients admitted to our liver unit and/or seen as an outpatient with CLD with or without cirrhosis and/or LT recipients who tested positive to SARS-CoV-2 infection. Cases were considered positive as defined by the detection of SARS-CoV-2 by reverse-transcription polymerase chain reaction (RT-PCR) on nasopharyngeal swabs.; Results: Between April 1 and July 31, 2020, 5,637 were admitted to our liver unit and/or seen as outpatient. Among them, 42 were positive for SARS-CoV-2. Twenty-two patients had CLD without cirrhosis while 16 patients had cirrhosis at the time of the infection (13, 2, and 1 with Child-Pugh A, B, and C scores, respectively). Four were LT recipients. Overall, 15 of 42 patients (35.7%) were hospitalized; among them, 7 of 42 (16.7%) required respiratory support and 4 of 42 (9.5%) were transferred to the intensive care unit. Only 4 of 42 (9.5%) patients died: 2 with CLD without cirrhosis and 2 with CLD with cirrhosis. Overall survival was 90.5%.; Conclusion: This real-world study demonstrates an unexpectedly low prevalence and low mortality in the context of SARS-CoV-2 infection among patients with CLD with or without cirrhosis and LT recipients.; (Copyright © 2021 Canadian Association for the Study of the Liver.) |
| Competing Interests: | I Ruiz is a recipient of a fellowship grant from the Fondation du CHUM, Montréal, Québec, Canada. D Martel has served as an advisor and/or speaker for AbbVie and Gilead. The rest of the authors have no conflicts of interest to declare. |
| References: | J Viral Hepat. 2020 Dec;27(12):1504-1507. (PMID: 32668494); Gastroenterology. 2021 Aug;161(2):730-731. (PMID: 33631182); J Hepatol. 2021 Jul;75(1):226-228. (PMID: 33556419); Clin Gastroenterol Hepatol. 2021 Jul;19(7):1469-1479.e19. (PMID: 32950749); Gut. 2021 Mar;70(3):531-536. (PMID: 32660964); Lancet Gastroenterol Hepatol. 2020 Nov;5(11):1008-1016. (PMID: 32866433); Hepatol Int. 2020 Sep;14(5):690-700. (PMID: 32623632); Gastroenterology. 2021 Mar;160(4):1151-1163.e3. (PMID: 33307029); Nat Rev Gastroenterol Hepatol. 2021 May;18(5):348-364. (PMID: 33692570); Clin Gastroenterol Hepatol. 2021 Mar;19(3):597-603. (PMID: 32553907); Liver Int. 2021 Apr;41(4):720-730. (PMID: 33351265); J Hepatol. 2020 Nov;73(5):1063-1071. (PMID: 32526252); J Hepatol. 2021 Mar;74(3):567-577. (PMID: 33035628); Clin Res Hepatol Gastroenterol. 2021 Jul;45(4):101639. (PMID: 33636654); Nat Rev Microbiol. 2021 Mar;19(3):141-154. (PMID: 33024307) |
| Contributed Indexing: | Keywords: COVID-19; SARS-CoV-2; chronic liver disease; cirrhosis; liver transplantation |
| Entry Date(s): | Date Created: 20220822 Latest Revision: 20220823 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC9235123 |
| DOI: | 10.3138/canlivj-2021-0022 |
| PMID: | 35989892 |
| Database: | MEDLINE |
Journal Article